EN: Patent granted for therapeutic antibodies against Alzheimer's disease
Conformational specific antibodies against Abeta 1-42, pyroglutamate 3-42 and 4-42 oligomers: Passive immunization with the antibodies rescue memory deficits in preclinical Alzheimer models, reduce plaque load and neuron loss in the hippocampus (US patent granted April 11, 2017).